Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Coffee Consumption Linked to Genes
Researchers have identified a gene that influences coffee consumption. The gene is thought to relate to caffeine breakdown.
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Biological Barcodes Using CRISPR
Using genome editing tools, researchers are getting closer to understand differentiation of various cell types during development.
Controlling DNA Repair
Scientists discover that DNA repair outcomes following CRISPR-Cas9 cleaving are non-random and can be harnessed to produce desired effects.
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Creating Embryos with 'Heteroplasmy'
New discovery in genetic research could lead to treatments for mitochondrial diseases.
Scroll Up
Scroll Down

Sequence-Specific DNA Assay
Bookmark and Share

Molecular Devices

Measurement of specific DNA sequences can be achieved using the Threshold® System. Biotinylated and fluoresceinated oligonucleotide probes specific to the target sequence to be measured are used with the Immuno Ligand Assay (ILA) kit components. The probes are chosen so that they both anneal to the same strand of the target, adjacent to each other. DNA samples to be measured are digested with an appropriate restriction enzyme to liberate the target sequence on a small DNA fragment. The digested DNA is denatured in the presence of an excess of the biotinylated and fluoresceinated probes. The probes and denatured target are allowed to anneal, generating probe-target hybrids. These probe-target hybrids are captured on the biotinylated Threshold sticks using the ILA capture reagent (streptavidin) which binds to the biotinylated probe. The captured probe-target hybrids are then detected and quantitated using the ILA enzyme reagent (antifluorescein- urease conjugate) which binds to the fluoresceinated probe. This application note is intended as a guide and does not represent a validation of this assay, nor necessarily the optimal performance parameters for all probe and target DNA combinations.


Related Content

Molecular Insight Pharmaceuticals, Inc. Elects a New Board of Directors
The new Board will support the Company’s strategic focus on the discovery, development, and commercialization of radiopharmaceuticals for molecular imaging and targeted radiotherapy of prostate cancer.
Wednesday, February 29, 2012
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!